Kite Pharma, Inc. – Colorado Center Office Lease (November 9th, 2016)
This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between CA-COLORADO CENTER, L.L.C., a Delaware limited liability company ("Landlord"), and KITE PHARMA, INC., a Delaware corporation ("Tenant").
Kite Pharma, Inc. – Research Collaboration and License Agreement (August 8th, 2016)
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (the "Agreement"), effective as of June 1, 2016 (the "Effective Date"), is made by and between CELL DESIGN LABS, INC., a Delaware corporation with its principal place of business at 4165 Canyon Road, Lafayette, CA 94549 ("CDL"), and KITE PHARMA, INC., a Delaware corporation with registered address at 2225 Colorado Avenue, Santa Monica, CA 90404 ("Kite"). CDL and Kite are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
Kite Pharma, Inc. – RESEARCH COLLABORATION AND LICENSE AGREEMENT by and Between AMGEN INC. And KITE PHARMA, INC. Dated as of December 31, 2014 (August 8th, 2016)
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is entered into as of December 31, 2014 (the "Signing Date") by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 ("Amgen"), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 ("Kite"). Kite and Amgen are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
Arno Therapeutics, Inc – Contract (March 11th, 2016)
Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Document Type Amendment Flag Document Period End Date Trading Symbol Entity Registrant Name Entity Central Index Key Working Capital Information [Abstract] Working Capital Information [Text Block] LIQUIDITY AND CAPITAL RESOURCES Working Capital Information Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share [Text Block] BASIC AND DILUTED INCOME/(LOSS) PER SHARE Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE OF FINANCIA
Contract (April 25th, 2012)
-5043 -10043 12414713 13794 -8794 -2576515 -2592015 13794132 13794 1706 15199932 -12894810 24099716 24100 28070642 5103618 -26026406 24149405 24150 31105874 3175718 2982150 -33898703 27085824 27086 36853767 51938 1069085 -39930194 219095 3665953 34630 34629794 10000000 3597250 3378155 84430 0.001 42492432 3665953 2596868 34629794 0.001 16765 100000000 332380 652275 -39930194 34629794 34630 42492432 51938 541447 -44814980 271298 1372170 39712 39712231 10000000 1310488 1039190 38892 0.001 45605991 1372170 830723 39712231 0.001 9744 100000000 437837 64718 -44814980 39712231 39712 45605991 -10043 -10043 1379419 13794 13794132 -8794 5000 51938 64718 29975187 -473946 793965 150105 1836735 -32704479 288000 -36724 106830 10305460 1273734 -44814980 5500000 -329664 29995891 3
Cougar Biotechnology Inc – Form of Tender and Support Agreement (May 26th, 2009)
This TENDER AND SUPPORT AGREEMENT, dated as of May 21, 2009 (this Agreement), is by and among [Alan H. Auerbach, Arie S. Belldegrun, or Horizon BioMedical Ventures, LLC, a Delaware limited liability company] (Stockholder), Johnson & Johnson, a New Jersey corporation (Parent), and Kite Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (Purchaser). Capitalized terms used but not defined herein have the meanings assigned to them in the Agreement and Plan of Merger, dated as of the date of this Agreement (together with any amendments or supplements thereto, the Merger Agreement), by and among Parent, Purchaser and Cougar Biotechnology, Inc., a Delaware corporation (the Company).
Paramount Acquisition – Contract (November 1st, 2007)
VOTING AGREEMENT, dated as of October 26, 2007 (this Agreement), among the persons listed under the caption Chem Rx Group on the signature page hereto (the Chem Rx Group), the persons listed under the caption Paramount Group on the signature page hereto (the Paramount Group), and Paramount Acquisition Corp., a Delaware corporation (Paramount).
Paramount Acquisition – STOCK PURCHASE AGREEMENT Dated as of June 1, 2007 Among PARAMOUNT ACQUISITION CORP., B.J.K. INC. And THE STOCKHOLDERS OF B.J.K. INC. (June 4th, 2007)
STOCK PURCHASE AGREEMENT, dated as of June 1, 2007 (this Agreement), among Paramount Acquisition Corp., a Delaware corporation (Paramount), B.J.K. Inc., a New York corporation doing business as ChemRx (the Company), and the stockholders of the Company listed on Exhibit A hereto (each a Seller and collectively, the Sellers)
Paramount Acquisition – Paramount Acquisition Corp. 787 7th Avenue, 48th Floor New York, New York 10019 (May 15th, 2007)
Cougar Biotechnology Inc – Employment Agreement (October 2nd, 2006)
"Market Capitalization" means the aggregate value of the Company's issued and outstanding capital stock, as determined by multiplying the closing sale price of the Company's common stock as reported on the OTC Bulletin Board or such other exchange or automated quotation system as the common stock is then listed or quoted by the total number of issued and outstanding shares of the Company's capital stock on a fully-diluted basis (i.e., assuming the issuance of all shares issuable upon the exercise of outstanding options, warrants and other convertible securities); provided, however, that in the event the Company has outstanding a class or series of capital stock that is convertible into common stock, the number of issued and outstanding shares of such convertible class or series of stock shall be deemed to be the number of shares of common stock issuable upon conversion ther
Cougar Biotechnology Inc – Contract (August 16th, 2006)
Schedule identifying material details of warrants issued by the Company substantially identical to the Warrant filed in Exhibit 4.1 (as incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form SB-2 filed on May 3, 2006 (SEC File No. 333-133779)).
Cougar Biotechnology Inc – Scientific Advisory Agreement (May 3rd, 2006)
THIS SCIENTIFIC ADVISORY AGREEMENT (this "Agreement"), effective as of the ____ of December, 2003, is by and between ARIE BELLDEGRUN, M.D., having an address at _______________________________ (hereinafter referred to as "ADVISOR") and Cougar Biotechnology, Inc., a Delaware limited liability corporation having offices at 10940 Wilshire Blvd. Suite 600, Los Angeles, CA 90024 ("COUGAR").
Cougar Biotechnology Inc – Scientific Advisory Agreement Amendment No. 1 (May 3rd, 2006)
This Amendment No. 1 (this "Amendment") effective this 24th day of August, 2004 hereby amends that certain Scientific Advisory Agreement (the "Agreement") between ARIE BELLDEGRUN, M.D., having an address at 10833 Le Conte Avenue, Los Angeles, CA 90095 (hereinafter referred to as "ADVISOR") and Cougar Biotechnology, Inc., a Delaware limited liability corporation having offices at 10940 Wilshire Blvd. Suite 600, Los Angeles, CA 90024 ("COUGAR"). Capitalized terms used herein but not otherwise defined shall have the meaning ascribed to such term in the Agreement.
Paramount Acquisition – September 7, 2005 (September 21st, 2005)
Paramount Acquisition – September 7, 2005 (September 8th, 2005)
Paramount Acquisition – Stock Escrow Agreement (August 3rd, 2005)
Paramount Acquisition – July 25, 2005 (August 3rd, 2005)
Paramount Acquisition – Registration Rights Agreement (August 3rd, 2005)